GenSight Biologics has postponed its plans to go public after repeatedly downsizing its ambition, marking the latest setback for Wall Street-bound biotechs dealing with a sectorwide downturn. The Parisian company set out to raise $100 million with its first filing over the summer, gradually scaling back its planned offering before settling on an effort to price about 4.7 million shares at $13 to $15 each. That goal will now have to wait as the biotech put on hold its Nasdaq debut, which would have helped fund its work to develop a gene therapy for rare, vision-destroying diseases. More